CAS: 15985-39-4; (2S)-2-Amino-4-(S-Methylsulfonimidoyl)Butanoic Acid

相似化合物

1982-67-8 83730-53-4 3226-65-1

上下游产品

CAS号21752-31-8 [R-(R*,S*)]-S-(... | CAS号21752-32-9 L-Methionine [S...

Tert-Butyl (2S)-2-[(Tert-Butoxycarbonyl)Amino]-4-[n-(Tert-Butoxycarbonyl)-S-Methylsulfonimidoyl]-Butanoate置于盐酸,水体系中,化学反应 3.0H,以66%的收率获得l-蛋氨酸磺酸盐
参考文献:铑催化的氨基甲酸酯向亚砜的硝基苯转移合成氨基磺酸亚砜肟.
标题:铑催化的氨基甲酸酯向亚砜的硝基苯转移合成氨基磺酸亚砜肟.
摘要:磺胺嘧啶对于掺入药物化合物具有相当大的兴趣.在温和的条件下,通过铑催化的氨基甲酸酯向亚砜的转移,可以方便地合成n保护的亚砜亚砜.制备了4元硫杂环丁烷-肟酮的第一个实例.带有boc和cbz基团的磺胺嘧啶对进一步的交叉偶联反应稳定,并易于脱保护.该方法可以促进提供改进的(整体)脱保护策略的nh-亚砜肟类的制备,这在甲硫氨酸亚砜(mso)的合成中得到了说明.
Doi:10.1021/acs.Joc.5B00844

专利信息

专利号:US-2004033532-A1
优先权日:2002-08-08
标题 :Use of three-dimensional crystal structure coordinates to design and synthesize domain-selective inhibitors for angiotensin-converting enzyme (ACE)
发明人：EHLERS MARIO R W; HOLMQUIST BARTON
摘要:It has now been discovered that the use of the three-dimensional crystal structure coordinates of angiotensin-converting enzyme (ACE) will enable the design and synthesis, by means of computational chemistry and structure-guided drug design, of inhibitors of ACE that are highly selective and specific for either the N domain or the C domain of the enzyme, for the treatment of diverse diseases. The invention also relates to methods and processes for the structure-guided design and synthesis of dual N- and C-domain ACE inhibitors, and inhibitors that operate by competitive, non-competitive, uncompetitive, and irreversible mechanisms.

专利号:US-2024010686-A1
优先权日:2020-11-09
标题 :Dna construct for stably producing empty capsids of the foot-and-mouth disease virus in mammalian cells; processes, uses, and compositions thereof
发明人：MIGNAQUI ANA CLARA; WIGODOROVITZ ANDRES; DUROCHER YVES
权利人:INSTITUTO NAC DE TECNOLOGIA AGROPECUARIA; NAT RES COUNCIL CANADA
摘要:Methods and compositions for increasing the production of large amounts of empty capsids of the foot-and-mouth disease virus (FMDV) in a stable manner in mammalian cells by regulating the expression of FMDV 3C protease. The instant methods and compositions are based on the fact that a decreased expression of 3C protease results in a reduced cell toxicity and an increased synthesis of viral capsid proteins, as well as production of recombinant empty capsids. The invention provides recombinant plasmids that direct the expression of P1, 3C, and the use of the plasmids for producing new stable cell lines capable of generating high titers of FMDV empty capsids. The invention provides methods for regulating the expression of the FMDV 3C protease gene at a transcriptional and translational level in order to achieve the required process level of 3C protease for the selection process, as well as the production process.

专利号:WO-2023187827-A1
优先权日:2022-03-30
标题:A pharmaceutical composition comprising an inhibitor of glutamine synthetase enzyme to combat artemisinin resistance in malaria
发明人：ARUN NAGARAJ VISWANATHAN; PADMANABAN GOVINDARAJAN; GHOSH SOURAV; KUNDU RAJIB; CHANDANA MANJUNATHA; ANAND ADITYA
权利人:INST OF LIFE SCIENCES
摘要:The present disclosure relates to a pharmaceutical composition to combat artemisinin resistance in malaria with the identification of Plasmodium falciparum (Pf) glutamine synthetase (GS) as a drug target. Pf Gs is important for maintaining asparagine levels in the parasite and promote protein synthesis. Since ART-resistant parasites undergo fitness loss in amino acid/nutrient- limiting conditions and GS levels are upregulated during ART exposure, targeting Pf GS and asparagine requirement can be harnessed to prevent ART resistance. The present disclosure also provides a method of suppressing the growth of Plasmodium falciparum and a method of treating malaria using GS inhibitors.

专利号:US-2022089775-A1
优先权日:2019-05-31
标题:Multiply auxotrophic cell line for the production of recombinant proteins and methods thereof
发明人：CHASIN LAWRENCE; ZHANG QINGHAO; DU ZHIMEI
权利人:UNIV COLUMBIA; MERCK SHARP & DOHME
摘要:The present invention provides, inter alia, a multiply auxotrophic cell line that is deficient in genes encoding enzymes that catalyze steps in the de novo synthesis of the pyrimidine and purine pathways, such as, e.g., uridine monophosphate synthetase (UMPS) and 5-aminoimidazole-4-carboxamide ribonucleotide formyltransferase/IMP cyclohydrolase (ATIC), respectively, for the production of recombinant proteins such as recombinant monoclonal and bispecific antibodies. Methods for preparing the multiply auxotrophic, in particular the doubly auxotrophic and octa-auxotrophic cell lines disclosed herein, methods for selecting a cell expressing a protein of interest, methods for producing a protein of interest, methods for optimizing the activity of a protein of interest, and kits for selecting a cell expressing a protein of interest, are also provided. In addition, recombinant proteins such as antibodies, including monoclonal and bispecific antibodies, made by the methods of the present disclosure are also provided.

专利号:WO-2024227949-A1
优先权日:2023-05-04
标 题:Screening and uses of glutamine synthetase modulators
发明人：MARTINS GARCIA BRUNA; FARAH PERNAS LENA
权利人:MAX PLANCK GESELLSCHAFT
摘要:The present invention relates to an in vitro bioassay to identify glutamine synthetase activators and inhibitors on the basis of one or more glutamine markers such as citrate, a metabolite derived from the mevalonate pathway, a glutamine responsive mRNA or proteins, such as HMGCR or SREBP2. Disclosed herein are also glutamine synthetase activators and inhibitors identified by the inventive method for use to stimulate or inhibit the synthesis of a metabolite derived from the mevalonate pathway, such as cholesterol, and to treat a disease associated with deregulated levels of said metabolite, such as cancer.

专利号:US-7504231-B2
优先权日:2001-09-13
标题:Method of alleviating chronic pain via peripheral inhibition of neurotransmitter synthesis
发明人：MILLER KENNETH E
权利人:UNIV OKLAHOMA
摘要:A composition having sustained pain-relieving properties such that the composition may be administered to a subject to alleviate chronic pain. The composition includes an effective amount of at least one inhibitor of neurotransmitter synthesis. A method for alleviating chronic pain in a subject for an extended period of time is also disclosed, in which the compound is administered to a subject suffering from chronic pain at a site of inflammation such that the administration of the compound results in a reduction in at least one of thermal and mechanical pain responses at the site of inflammation for a period of at least two days without any resulting acute pain behavior. The composition may further include an effective amount of at least one compound having analgesic effects such that the composition also alleviates acute pain.